Ligandrol (LGD-4033)
lig-AN-drol
Category
Compound type
Phase / Status
Development suspended by AbbVie in 2020. Originally developed for muscle wasting and osteoporosis. Same compound as LGD-4033. Different name, same molecule.
Standard Dose
Once daily
Half-life
Plasma elimination
Route(s)
Intramuscular, Subcutaneous or Oral
Research Stage
Research phase not specified; exercise appropriate caution.
Overview
Ligandrol is LGD-4033 - same molecule, different brand name. Think of it as a stronger Ostarine. Builds muscle fast, perfect for bulking phases. Originally meant for elderly patients losing muscle. More potent than milder SARMs but with more testosterone suppression. Same side effects, same benefits - just a different name on the bottle. Still needs PCT despite what bro-science says.
Plain-language summary
Ligandrol is LGD-4033 - same molecule, different brand name. Think of it as a stronger Ostarine. Builds muscle fast, perfect for bulking phases. Originally meant for elderly patients losing muscle. More potent than milder SARMs but with more testosterone suppression. Same side effects, same benefits - just a different name on the bottle. Still needs PCT despite what bro-science says.
Administration Routes
- Intramuscular
- Subcutaneous
- Oral
Also known as
Mechanisms
Selective Androgen Receptor Modulator (SARM) - binds to androgen receptors in muscle and bone tissue. Same mechanism as LGD-4033 because it IS LGD-4033.
Detailed mechanism
LGD-4033 (Ligandrol) is a non-steroidal SARM that binds the androgen receptor with high affinity and selectivity, demonstrating full agonist activity in skeletal muscle and bone while exhibiting partial agonist or antagonist activity in tissues such as the prostate, reflecting tissue-specific coactivator recruitment differences. It activates AR-dependent transcriptional programs (IGF-1, follistatin, myosin heavy chain genes) that drive satellite cell proliferation, nitrogen retention, and net protein anabolism, producing lean mass gains comparable in quality to low-dose testosterone without significant androgenization of non-target tissues. HPG axis suppression is nonetheless dose-dependent and clinically significant, with LH and FSH falling substantially at doses above 1mg/day and recovering over several weeks post-cycle.
Safety
Side effects
- Testosterone suppression (dose-dependent)
- May lower HDL cholesterol
- Water retention at higher doses
- Rare liver enzyme elevation
- Headache at high doses
Reported benefits
- Significant muscle mass gains
- Increased strength levels
- Improved bone density
- Great for bulking phases
- Oral administration - no pins
- Less liver toxicity than oral steroids
Safety profile
Limited human safety data. Use with caution and under appropriate supervision.
Clinical trials
Research studies ongoing. Not yet in formal clinical trials.
Structure
Verified structure
Ligandrol (LGD-4033)
No exact public structure match was confirmed, so the app will render a formula-backed illustration.
- Chemical Formula
- C28H25F2N3O2
- Molecular Weight
- 460.93 g/mol
- CAS Number
- 1182387-74-9
Stack Context
Stacks with
References
- 1View source
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men (J Gerontol A Biol Sci Med Sci)
2013
- 2View source
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit (Mol Interv)
2009
- 3View source
LGD-4033 (Ligandrol) Phase 2 Clinical Study Registry (ClinicalTrials.gov NCT01009762)
2013
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.